IL17A and psoriasis: Although the IL-23/ Th17/ IL-17 pathway has been established as the key major axis in psoriasis [86], there is also a subset of Western and Asian patients whose symptoms cannot be alleviated by pharmaceutical therapeutics targeting this pathway [87].